Neil H. Segal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Phase 2 study of adjuvant botensilimab in combination with balstilimab in patients with microsatellite-stable colorectal cancer and persistent circulating tumor DNA following surgery and chemotherapy.

  Journal of Clinical Oncology · 2026-05-28

• daNIS-3: A phase II platform study of NIS793 and anti–PD-1 combined with standard of care (SoC) anti-cancer therapy for the second-line (2L) treatment (tx) of microsatellite-stable colorectal cancer (MSS CRC).

  Journal of Clinical Oncology · 2026-05-27

• Abstract 241: Targeted drug screening identifies novel compounds enabling accelerated mismatch repair deficiency (MMRd) for immunotherapy sensitization.

  Cancer Research · 2026-04-03

• Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer

  Clinical Cancer Research · 2025-10-30 · 6 citations

• 1558P Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFR×CD28 bispecific antibody (bsAb)

  Annals of Oncology · 2025-09-01

• The value of MRI and flexible sigmoidoscopy in detecting tumor regrowth in watch and wait rectal cancer patients undergoing active surveillance after total neoadjuvant therapy

  Surgical Endoscopy · 2025-07-14 · 3 citations

• 8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases

  Annals of Oncology · 2025-07-01 · 2 citations

• Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer

  Cancer Cell · 2025-06-12 · 10 citations

• Genomic characterization of anal canal squamous cell carcinoma (ASCC) and outcomes on matched targeted therapy.

  Journal of Clinical Oncology · 2025-05-28

• Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Nonoperative Management of Mismatch Repair–Deficient Tumors

  New England Journal of Medicine · 2025-04-27 · 160 citations

• Abstract 3391: Clonality and allelic imbalance of driver genes in a large retrospective cohort of colorectal cancer patients

  Cancer Research · 2025-04-21

• Abstract 1152: The landscape of copy number variations following WGD in 5,980 colorectal cancers

  Cancer Research · 2025-04-21

• RETRACTED: Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumorsPreprint

  Research Square · 2025-03-12

• Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).

  Journal of Clinical Oncology · 2025-01-27 · 5 citations

• Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.

  Journal of Clinical Oncology · 2025-01-27 · 8 citations

• Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait

  Diseases of the Colon & Rectum · 2024-11-18 · 10 citations

• ASO Visual Abstract: Outcomes of Distal Rectal Cancer Patients Who Did Not Qualify for Watch-and-Wait—Comparison of Intersphincteric Resection Versus Abdominoperineal Resection

  Annals of Surgical Oncology · 2024-11-04 · 1 citations

• Outcomes of Distal Rectal Cancer Patients Who Did Not Qualify for Watch-and-Wait: Comparison of Intersphincteric Resection Versus Abdominoperineal Resection

  Annals of Surgical Oncology · 2024-10-12 · 6 citations

• P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update

  Journal of Thoracic Oncology · 2024-10-01